Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?

Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors

(2014) Poorval M. Joshi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

BRCA1 Pathway Function in Basal-Like Breast Cancer Cells

(2014) S. J. Hill et al.   MOLECULAR AND CELLULAR BIOLOGY

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

(2013) E H Lips et al.   BRITISH JOURNAL OF CANCER

Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition

(2013) Kenji Sakogawa et al.   CANCER SCIENCE

Differential Chemotherapeutic Sensitivity for Breast Tumors With "BRCAness": A Review

(2013) P. Chalasani et al.   ONCOLOGIST

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

(2012) V Abkevich et al.   BRITISH JOURNAL OF CANCER

Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation

(2012) T. Popova et al.   CANCER RESEARCH

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy

(2010) E. H. Lips et al.   ANNALS OF ONCOLOGY

Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer

(2010) Panagiotis A. Konstantinopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer

(2010) Daniel P. Silver et al.   JOURNAL OF CLINICAL ONCOLOGY

BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors

(2010) Jurgen Veeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

(2010) Peter Bouwman et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors

(2008) Xuesong Liu et al.   ANALYTICAL BIOCHEMISTRY